Concord Medical Services Holdings Limited is one of China’s leading providers of radiation oncology services, offering comprehensive cancer treatment solutions through partnerships with public hospitals. Founded in 2006 and listed on the New York Stock Exchange in 2017 under the ticker CCM, the company develops, equips and operates modern radiotherapy centers across mainland China. Concord Medical’s model integrates capital investment, clinical expertise and high‐precision technology to expand access to radiotherapy in cities where advanced oncology services have historically been limited.
The company’s core services include the design, construction and operation of radiation oncology centers, equipment procurement and installation, routine maintenance, clinical physics support and staff training. Utilizing a range of advanced platforms—such as intensity‐modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), image‐guided radiotherapy (IGRT) and brachytherapy—Concord Medical delivers tailored treatment plans, quality assurance and remote dosimetry through a centralized planning platform. These integrated services help hospital partners enhance patient throughput and improve treatment outcomes.
Concord Medical has established a network of over sixty oncology centers spanning more than twenty provinces, predominantly serving tier‐2 and tier‐3 cities. The company’s franchise‐style collaborations with leading public hospitals allow rapid scaling while maintaining consistent clinical protocols and operational standards. By leveraging shared resources and a proprietary information system, Concord Medical provides streamlined workflows and data analysis tools that support clinical decision making and optimize utilization of radiotherapy equipment.
Governed by a management team with deep experience in healthcare, finance and oncology, Concord Medical is guided by a co‐founder and chairman who has led the company since inception, alongside a chief executive officer with a background in clinical operations and research. Supported by a board that includes senior medical experts, the company continues to expand its footprint, pursuing strategic partnerships and new technologies to address the growing demand for high‐quality cancer care in China.
AI Generated. May Contain Errors.
